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EDITORIAL
CURTAILING MATERNAL TO CHILD TRANSMISSION OF HIV
The overall risk of transmission of HIV from mother to
child is around 15-25% for non-breast feeding mothers,
and doubles to 25-45% for breast-feeding mothers(1,2).
Thus, in a country like Uganda where mother to child
transmission (MTCT) accounts for about 10% of total
cases, the MTCT rate is estimated at 26% (3). It has been
suggested that 60-70% of transmissions occur around the
time of delivery, with the remainder mostly late in the third
trimester (30%) and the rest, postnatally (10%) through
breastfeeding(4). In general, a healthy placenta appears to
protect the foetus in utero from HIV in maternal blood for
most of the gestation. The integrity of the placental
protection against HIV may, though rarely, be breached
by infections or drugs which can damage the vasculature
and allow mixing of the two circulations(5,6). For the
majority of women with HIV, it means then that
interventions to reduce the risk of transmission should be
focused on the last trimester of pregnancy and the risk
factors that increase the chances of MTCT, giving women
and clinicians time to plan ahead.
The most important determinant of risk is the maternal
plasma viral load. However, other risk factors which have
been identified, independent of the maternal viral load,
include genital tract infections and ulcers, HIV content of
maternal cervicovaginal secretions and breast
infections(7,8). It has been reported by Kenyan researchers
that mother-child class 1 HLA concordance increases
perinatal HIV-1 transmission(9). No clear cut differences
in transmission has been found among the various HIV-1
subtypes or clades(10-12). A study from Kenya reports a
strong association between decreased HIV-1 infection
risk in perinatally exposed infants and possesion of a
cluster of closely related class 1 HLA alleles ( A2/6802
supertype)(13), Maternal viral load is related to CD4
count and the progression of HIV disease –a low CD4
count and more advanced HIV also increase the risk of
vertical transmission. Primary infection with HIV in a
pregnant or lactating woman also increases the risk of
transmission, as in the first weeks of infection the plasma
viral load is very high, before the immune response to HIV
brings the level of the virus down(2). It is, thus, relevant
that in this issue of the journal, Makokha et al(14) found
that HIV infected pregnant women who responded to
monotherapy with zidovudine with a rise in absolute CD4
counts were less likely to transmit the infection to their
newborns.
To take up an intervention to reduce the risk of
MTCT of HIV, a woman needs to know that she is
seropositive. An HIV test should, therefore, be
recommended to all pregnant women as part of normal
antenatal care. An HIV test in pregnancy requires an
infrastructure which can deliver counseling, testing and
reliable serological results. In as much as such voluntary
counseling and testing has been acceptable in principle in
s m  countries, like Uganda(15), much needs to be done
to ensure confidentiality and allay women’s fears of
stigmatisation and discrimination during delivery. Such
an infrastructure of antenatal care should not be devoted to
HIV, but makes an opportunity to improve the overall
manag ment of women’s health in pregnancy.
Int rventions to reduce HIV transmission should go along
with a package of best antenatal care for all pregnant
women, both positive and negative.
The World Health Organisation strategy includes
simple measures for all-vitamins (including folate) and
iron supplements; anti-malarials (where appropriate); and
improved obstetric care as part of the Making Pregnancy
Safer Initiative(16). Better health for all women, is
undoubtedly related to status in society and the political
will for change. To carry through effective programmes
for p egnant women, including those with HIV,
gover ments need to demonstrate r al financial
commitment to women and their children – a difficult task
in r source poor countries.
From the known risks of transmission described
above, the interventions to reduce transmission can be
considered under four categories:
 (i) reduction of maternal viral load,
(ii) avoidance of labour and the birth canal,
(iii) keeping the birth canal free of infections and ulcers
and
(iv) avoidance of breast milk. Currently different
approaches are taken according to the resources
available.
Monotherapy with zidovudine was the first treatment
demonstrated to reduce MTCT by nearly 70% to a rate of
around 6-8% in a randomised controlled trial(17). Pre-
labour Caesarean section has been shown to reduce the risk
of transmission of HIV in women with all levels of viral load
by up to 70% in a randomised controlled trial and 50% in a
la ge meta-analysis(18,19). Zidovudine and a pre-labour
Caesarean section reduced the risk of transmission to less
than 2% for women at any level of viraemia, so this can still
be co sidered as an option for a woman who wishes to
restrict antiretroviral therapy exposure during
pr gnancy(18,19). Dual therapy with zidovudine and
lamivudine reduced the late of transmission to around 2%,
but is not adequate treatment for the mother, with rapid
development of resistance to lamivudine(20). There have
been no randomised controlled trials of triple therapy in
pregnancy, but delivery at below detectable viral load is
associated with a very low rate of transmission(21). Thus
women who require combination therapy for treatment of
their HIV will concomitantly greatly reduce the risk of
ransmission when their viral load is suppressed. Whether
a pre-labour Caesarean section has any additive effect at
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undetectable viral load is not known. Last minute treatment,
in labour or even after delivery within the first 48 hours for
the infant will also reduce transmission, and should be
considered for women who present late(22). Women are
being treated with many antiretroviral therapy combinations,
exposure to these drugs in pregnancy has not been associated
with any specific or an increased rate of teratogenic
effects(23). However, an increased risk of premature delivery
has been suggested for women on combinations with protease
inhibitors(24).
In the original zidovudine monotherapy study,
treatment was started as soon as possible after 14 weeks
gestation, continued throughout pregnancy, administered
intravenously during delivery and to the infant for six-
weeks after birth(17). This regime was long and expensive
and not appropriate for countries where mothers may not
present early in pregnancy and where there is a dearth of
resources. Short-course zidovudine commenced at 36
weeks gestation, continued orally during delivery, with
none to the infant, has been associated with a 50% reduction
in HIV transmission to a rate of 9.4% (25). A further study
of different ime courses of zidovudine monotherapy
demonstrated further reduced transmission if treatment
was started at 28 weeks (transmission rate 6.7%) rather
than 35 weeks (transmission rate 10.6%) gestation, but
little effect of the length of treatment of the infant whether
3 days or 6 weeks(26). Where women can be supplied with
formula feed, short course zidovudine with or without
Caesarean section will reduce the vertical transmission
rate of HIV to less than 10%.
In countries with limited resources interventions
should as far as possible benefit all women, both HIV
positive and negative, and efforts need to be directed at
general improvements in antenatal and perinatal care.
Genital tract infections, use of medroxyprogesterone or
oral contraceptives and vitamin A deficiency have been
associated with increased risk of MTCT of HIV (27, 28).
It is conceivable that treating these infections with
antibiotics and other agents could reduce MTCT of HIV
(29), as might avoiding the above means of contraception.
Cleansing of the birth canal with chlorhexidine in labour(30,
31) and antenatal and postnatal maternal supplementation
with vitamins(28,32,33) are some of the other modalities
which have been tried in Kenya and Tanzania, with
varying results.
Caesarean section is not an affordable or necessarily
safe option for many poor women, but short course, or
even in labour only antiretroviral therapy may be possible
as has been demonstrated in some studies(34, 35). A very
simple regime of single dose nevirapine in labour and to
the infant at 48-72 hours compared to only a week of
zidovudine reduces transmission by about one-half(36,
37). A 35% reduction in transmission was subsequently
maintained up to one year in this breast feeding cohort(38).
This intervention is very cheap and can also be given to
women who present late, as is the case in many resource
poor settings, although to be maximally effective the drug
must be taken in early labour(39,40). The main drawback
of this i ervention is that resistance to nevirapine develops
in up to 20% of the women after the single dose and
although this may not be relevant for subsequent delivery
use, it is likely to reduce the effectiveness of the non-
nucle side class of drugs for any future combination
antiretroviral therapy regime. It had been suggested that
this regime could be offered to all women in labour,
without knowing their HIV status, however in one study it
was d monstrated that women were more likely to
remember to lake the drug if they were HIV infected(41).
In a resource poor setting in Kenya, it has been noted
that where mothers have access to clean water, formula
feeding is safe and reduces the risk of MTCT of HIV
c mpared to breast-feeding by 44% without any increase
in infant mortality by two years of age(42). Additionally,
an observational study from South Africa suggests that the
rate of breast-milk transmission may be less if women
exclusively breast-feed, giving absolutely no other
substances to their infants compared to mixed feeding
where infants are exposed to other oral antigens in the first
months of life(43). However, in Uganda, no correlation
was found between the detection of HIV- 1 in breast milk
or the duration of breastfeeding and transmission of HIV-
1 infection(44). Further, a study in Tanzania has revealed
hat knowledge of HIV transmission through breastfeeding
is not associated with breastfeeding practices(45).
From the foregoing, it is evident that vertical
transmission of HIV can be significantly reduced using
various measures, either singly or in combination. The
ongoing studies on the molecular aspects of the HIV and
the host that influence MTCT are welcome. However,
more studies are required to shed more light on the cost –
effectiveness and safety of the modalities of intervention
currently available and their applicability in resource poor
countries. Ultimately, the ideal goal would be for all
moth rs to go into pregnancy uninfected and remain so
throughout the pregnancy, a gigantic task indeed for the
moment.
S.O. McLigeyo MBChB, MMed, Associate Professor,
Department of Medicine, College of Health Sciences,
University of Nairobi, P.O. Box 19676, Nairobi, Kenya.
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